About Sutro Biopharma
Sutro Biopharma is a publicly listed company based in United States founded in 2003. Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. Sutro Biopharma has raised $171.85 million across 11 funding rounds from investors including Merck, Citadel and Celgene. The company has 338 employees. Its website sutrobio.com draws about 12 thousand monthly visits. Sutro Biopharma offers products and services including XpressCF+ and iADCs. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its legal entity is SUTRO BIOPHARMA, INC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Sutro Biopharma was founded in 2003 in the United States within the biotechnology sector. Antibody-based therapeutics targeting cancer are developed using the XpressCF cell-free protein synthesis platform. Discoveries such as STRO-001 for B-cell malignancies and STRO-002 for ovarian and endometrial cancers have been enabled by this technology. Operations focus on advancing these treatments through research and development in oncology.
- Headquarters United States
- Employees 338
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website sutrobio.com
- Social LinkedIn X YouTube Threads
- Legal Name Sutro Biopharma, Inc.
- Annual Revenue$102.48 M (USD)65.18as on Dec 31, 2025
- Net Profit-$191.09 M (USD)15.99as on Dec 31, 2025
- EBITDA-$97.63 M (USD)57.78as on Dec 31, 2025
- Total Equity Funding$171.85M (USD)
in 11 rounds
- Latest Funding Round$85.4M (USD), Series E
Jul 2018
- InvestorsMerck
& 13 more
- Employee Count338
Products & Services of Sutro Biopharma
Sutro Biopharma offers a comprehensive portfolio of products and services, including XpressCF+ and iADCs.
Cell-free technology for protein expression in drug development.
Antibody-drug conjugates for targeted cancer treatments.
Apps and channels of Sutro Biopharma
its YouTube channel Sutro Biopharma has 70 subscribers and 30 videos.
Videos from Sutro Biopharma
The most watched videos on Sutro Biopharma's YouTube channel, Sutro Biopharma (70 subscribers). Click a video to play it here.
More on Sutro Biopharma.
Funding Insights of Sutro Biopharma
Sutro Biopharma has successfully raised a total of $171.85M across 11 strategic funding rounds. The most recent funding activity was a Series E round of $85.4 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $171.85M
- Total Rounds 11
- Last Round Series E — $85.4M
- First Round $500,000
(Sep 2005)
- Investors Count 14
Latest 10 of 11 funding rounds of Sutro Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2018 | $85.4M | Series E | – | Samsara BioCapital, Citadel | |
| Dec 2013 | $26M | Series D | – | Alta Partners, Skyline Ventures | |
| May 2012 | $16.5M | Series C | – | Skyline Ventures | |
| Nov 2010 | $20M | Series C | – | Skyline Ventures | |
| Mar 2009 | $15M | Series B | – | Alta Partners, SV Health Investors | – |
| Nov 2007 | $500,000 | Grant | – | – | |
| Oct 2007 | $6.44M | Series A | – | – | – |
| Apr 2007 | $1.5M | Seed | – | – | – |
| Dec 2006 | $801,755 | Seed | – | – | – |
| Nov 2006 | $200,000 | Seed | – | – | – |
14 investors in total: 14 institutional.
Investors in Sutro Biopharma
Sutro Biopharma has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, Citadel and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Venture capital investments are facilitated by Amgen-backed entity. | amgenbd.com | Thousand Oaks, United States | ||
Early-stage life sciences investments are targeted in the healthcare sector. | lillyventures.com | Indianapolis, United States | ||
US life sciences companies are invested in by Skyline Ventures. | skylineventures.com | Palo Alto, United States | ||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Biomedical innovations are transformed into therapies by Vida Ventures. | vidaventures.com | Boston, United States | ||
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States | |
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States | |
Operates as a hedge fund specializing in long/short equity strategies. | 2015 | nextheracapital.com | New York, United States |
Investor details for Sutro Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sutro Biopharma
142 people are tracked at Sutro Biopharma (63 in leadership, 19 in board & advisors, 60 in team); the tracked headcount is 338.
| Name | Role | Group |
|---|---|---|
Anne Borgman | Chief Medical Officer | Leadership |
William J. Newell | CEO | Leadership |
David Pauling | Chief Administrative Officer And General Counsel | Leadership |
Jane Chung | COO | Leadership |
Dan Elefant | Director, Purification MSAT | Leadership |
Richard Spanggord | Senior Director | Leadership |
Venkatesh Srinivasan | Chief Technical Operations Officer | Leadership |
Greg Chow | Chief Financial Officer | Leadership |
William F. Bleker | Vice President, Medical Safety & Pharmacovigilance | Leadership |
Lester Cacao | Director Of Enviroment, Health, And Safety | Leadership |
Nanette Damian | Executive Assistant To Chief Medical Officer | Leadership |
Jennifer Elkhoury | Associate Director, Supply Chain | Leadership |
Christina Susanto | Director, Intellectual Property & Corporate Counsel | Leadership |
Regina Cheng | VP of Finance | Leadership |
Krishna M Bajjuri | Senior Director, Chemistry | Leadership |
Jim Akins | Director Vivarium Operations | Leadership |
Steve Michel | VP Of Information Technology & Facilities Operations | Leadership |
Joseph Dittberner | Director of Facilities | Leadership |
Brian Vuillemenot | Senior Director, Safety Assessment | Leadership |
Margaret Wong | Associate Director, Quality Systems Compliance | Leadership |
122 more people are available in the full profile.
Complete people profiles for Sutro Biopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Sutro Biopharma
Sutro Biopharma is a publicly listed company on the NASDAQ with ticker symbol STRO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Sep 2018
- Listed onNASDAQ: STRO
- Listed entitySutro Biopharma, Inc.
- Exchange sectorHealth technology
- ISINUS8693672011
- Share price$11.01 (-17.09% on the day) · 2026-10-13
- Market capitalisation$182.6M
- EPS (diluted, trailing year)$-17.41
- Volume (last session)406,676
Financials of Sutro Biopharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $102.5M | -$191.1M | -$97.6M |
| 2024 | $62.0M | -$227.5M | -$231.2M |
| 2023 | $153.7M | -$106.8M | -$82.5M |
| 2022 | $67.8M | -$119.2M | -$120.7M |
| 2021 | $61.9M | -$105.5M | -$88.8M |
Detailed financial statements for Sutro Biopharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Sutro Biopharma
4 dated milestones of Sutro Biopharma across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Sutro Biopharma is founded.
- Funding First funding round of $500K.
- Funding Latest funding round, Series E, of $85.4M.
- IPO Lists on the stock exchange (IPO).
Competitors of Sutro Biopharma
Sutro Biopharma has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Sutro Biopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sutro Biopharma
The website of Sutro Biopharma (sutrobio.com) receives about 12.4K visits a month and ranks #2,081,214 among all websites worldwide, #2,839 in Biotechnology and Pharmaceuticals.
- Monthly visits12.4K
▲ 4.9% vs previous month
- Unique visitors5.4K
per month
- Global rank#2,081,214
among all websites
- Category rank#2,839
Health · Biotechnology and Pharmaceuticals
- Bounce rate49%
- Pages per visit1.5
- Average visit26 sec
- DevicesDesktop 32% · Mobile 68%
Websites whose visitors overlap most with Sutro Biopharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mbcbiolabs.com | 100% | #2,013,343 | View details | ||
| assemblybio.com | 99% | 5.8K | #3,402,677 | View details | |
| mazetx.com | 99% | 9.2K | #2,405,150 | View details | |
| allogene.com | 97% | 33.5K | #1,405,171 | View details | |
| astellasgenetherapies.com | 96% | 1K | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Sutro Biopharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Sutro Biopharma (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sutro Biopharma
Complete news archive for Sutro Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sutro Biopharma
Sutro Biopharma was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Sutro Biopharma is headquartered in United States.
Sutro Biopharma is a funded company, having raised a total of $171.85M across 11 funding rounds to date. The company's 1st funding round was a Seed of $200K, raised on Sep 2005.
Sutro Biopharma has 338 employees.
Annual revenue of Sutro Biopharma is $102.48M as on Dec 31, 2025.
Sutro Biopharma was founded in 2003 in the United States within the biotechnology sector. Antibody-based therapeutics targeting cancer are developed using the XpressCF cell-free protein synthesis platform. Discoveries such as STRO-001 for B-cell malignancies and STRO-002 for ovarian and endometrial cancers have been enabled by this technology. Operations focus on advancing these treatments through research and development in oncology.
Sutro Biopharma offers XpressCF+ and iADCs.
Yes, Sutro Biopharma is publicly traded on NASDAQ under the ticker symbol STRO.
Sutro Biopharma has 14 investors. Key investors include Merck, Citadel, Celgene, Tekla Capital Management, and Samsara BioCapital.
Sutro Biopharma operates through Sutro Biopharma, Inc..